Illumina (ILMN) Peer Comparison
$273.04
$7.32
(2.75%)
As on 02-Oct-2026 16:12EDT
Market cap
$41,229 Mln
Revenue (TTM)
$4,493 Mln
P/E Ratio
50.8
P/B Ratio
13.2
Div. Yield
0 %
Edit
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
41,229 | 241,264 | 168,712 | 148,864 | 140,427 |
Revenue ($ Mln) |
4,493 | 46,336 | 46,585 | 25,107 | 11,034 |
Net Profit ($ Mln) |
825.00 | 6,978.00 | 5,425.00 | 4,004.00 | 3,138.80 |
Net Margin (%) |
18.36 | 15.06 | 11.65 | 15.95 | 28.45 |
RoE (%) |
29.67 | 13.12 | 10.51 | 7.62 | 17.34 |
Price to Earnings |
50.85 | 35.40 | 31.55 | 39.51 | 46.06 |
Price-To-Book |
13.17 | 4.67 | 3.50 | 2.96 | 7.82 |
Income Statement ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,493.00 | 46,336.00 | 46,585.00 | 25,107.00 | 11,034.40 |
|
Cost of Revenue
|
1,492.00 | 27,323.00 | 20,123.00 | 10,416.00 | 3,676.80 |
|
Gross Profit
|
2,893.00 | 18,239.00 | 24,607.00 | 14,970.00 | 6,642.30 |
|
Operating Expenses
|
2,059.00 | 10,685.00 | 18,557.00 | 9,564.00 | 3,906.40 |
|
Operating Profit (EBIT)
|
942.00 | 8,327.00 | 7,932.00 | 5,127.00 | 3,451.20 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
1,015.00 | 7,609.00 | 7,511.00 | 4,762.00 | 3,805.80 |
|
Provision for Tax
|
190.00 | 597.00 | 2,086.00 | 758.00 | 647.90 |
|
Profit after Tax (Net Income)
|
825.00 | 6,978.00 | 5,425.00 | 4,004.00 | 3,138.80 |
|
Minority Interest
|
0.00 | -21.00 | 0.00 | 0.00 | -19.10 |
|
Consolidated Profit
|
484.00 | 3,580.00 | 3,420.00 | 2,105.00 | 0.00 |
Liabilities ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,838.00 | 52,679.00 | 51,110.00 | 52,581.00 | 18,168.40 |
|
Minority Interest
|
0.00 | -21.00 | 0.00 | 0.00 | -19.10 |
|
Non-Current Liabilities
|
2,234.00 | 45,298.00 | 39,639.00 | 31,681.00 | 656.00 |
|
Current Liabilities
|
1,578.00 | 15,069.00 | 17,814.00 | 8,105.00 | 1,922.90 |
|
Total Liabilities
|
6,644.00 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
Assets ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
3,816.00 | 89,809.00 | 84,698.00 | 78,986.00 | 11,333.90 |
|
Current Assets
|
2,834.00 | 23,365.00 | 24,517.00 | 13,381.00 | 9,542.70 |
|
Total Assets
|
6,644.00 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
|
Total Debt*
|
2,527.00 | 42,549.00 | 32,608.00 | 26,558.00 | 0.00 |
|
Net Current Assets
|
0.00 | 8,296.00 | 0.00 | 5,276.00 | 7,619.80 |
Cashflow ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,079.00 | 7,818.00 | 9,566.00 | 6,416.00 | 3,030.50 |
|
Cash Flow from Investing Activities
|
-55.00 | -4,047.00 | -2,422.00 | -1,196.00 | 665.80 |
|
Cash from Financing Activities
|
-744.00 | 1,801.00 | -6,309.00 | -2,961.00 | -2,364.10 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
16.55 | 7.69 | 10.03 | 5.25 | 16.46 |
|
ROE (%)
|
29.67 | 13.12 | 10.51 | 7.62 | 17.34 |
|
ROA (%)
|
9.69 | 5.76 | 4.69 | 4.24 | 14.06 |
|
EBIT Margin (%)
|
24.26 | 18.62 | 13.35 | 20.13 | 33.76 |
|
Net Margin (%)
|
18.36 | 15.06 | 11.65 | 15.95 | 28.45 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
4.93 | 7.23 | 8.06 | 4.56 | 20.66 |
|
EBIT Growth (%)
|
-27.62 | 1.20 | -26.60 | 15.73 | 24.96 |
|
Net Profit Growth (%)
|
-34.42 | 5.98 | -61.19 | 17.32 | 20.37 |
|
EPS Growth (%)
|
-32.04 | 7.77 | -61.19 | 20.09 | 21.65 |
|
Book Value Growth (%)
|
28.97 | 6.26 | 1.54 | 2.10 | 3.40 |
Valuation Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
23.76 | 32.43 | 33.55 | 45.04 | 71.47 |
|
Price / Book Value
|
7.42 | 4.09 | 4.20 | 3.10 | 11.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
14.49 | 21.61 | 19.48 | 25.42 | 49.76 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.74 | 0.00 | 0.48 | 0.00 |
|
Short term debt to equity ratio
|
0.21 | 0.06 | 0.06 | 0.03 | 0.00 |
|
Current Ratio
|
1.80 | 1.55 | 1.38 | 1.65 | 4.96 |
|
Quick Ratio
|
1.40 | 1.18 | 0.97 | 1.25 | 3.91 |
|
Interest Coverage
|
14.53 | 6.19 | 12.79 | 17.31 | -- |
Operating Efficiency Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.00 | 20.40 | 18.46 | 15.79 | 16.08 |
|
Asset Turnover
|
0.53 | 0.38 | 0.40 | 0.27 | 0.49 |
|
Receivable days
|
67.57 | 82.76 | 61.20 | 61.72 | 54.16 |
|
Inventory Days
|
140.41 | 72.19 | 117.44 | 91.69 | 177.54 |
|
Payable days
|
58.26 | 46.50 | 78.11 | 68.44 | 23.93 |
|
Cash Conversion Cycle
|
149.72 | 108.45 | 100.53 | 84.97 | 207.78 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
